Drug Profile
ZS 07
Alternative Names: ZS-07Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Zensun (Shanghai) Sci & Tech
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
- Discontinued Dyspepsia
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Dyspepsia in China (unspecified route) (Zensun (Shanghai) Sci & Tech pipeline, September 2023)
- 11 Sep 2023 Preclinical trials in Alzheimer's disease in China (unspecified route) (Zensun (Shanghai) Sci & Tech pipeline, September 2023)
- 11 Sep 2023 Zensun (Shanghai) Sci & Tech plans to initiate clinical trial for Alzheimer's disease in 2022 (Zensun (Shanghai) Sci & Tech pipeline, September 2023)